Jump to content
Advertisement

Advertisement

Search the Community

Showing results for 'DDW19' in content posted in IBS General Discussion and Managing Symptoms.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Community

  • Discussion
    • Welcome and Newly Diagnosed
    • IBS General Discussion and Managing Symptoms
    • Diarrhea predominant Irritable Bowel Syndrome (IBS-D), Post-Infectious IBS (PI-IBS) and Leaky Gas (LG), Incontinence or Odor.
    • Constipation predominant Irritable Bowel Syndrome (IBS-C) and Chronic Idiopathic Constipation (CIC)
    • IBS Diet, low FODMAP Diet and Nutrition
    • IBS Medications, Medical Foods and Fecal Microbiota Transplantation (FMT)
    • Women's Health Issues
    • IBS Patient Stories
    • IBS Podcasts and Videos
    • IBS Clinical Research Trials
    • IBS News Articles and Research Results
    • IBS Newsfeed
    • IBS Twitter feed
    • We Remember
    • Announcements

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

  1. Chey: Congenital sucrase-isomaltase deficiency may be under-diagnosed as it is generally not on the adult GI's radar Chey: CSID signs and symptoms are similar to IBS-D symptoms Chey: CSID could be considered for low FODMAP diet failures Chey: Sucrase-isomaltese deficiency could be seen in as high as 8% of patients. Gold standard for diagnosis is via assay; however, other less invasive testing could be considered. CSID has been associated with IBS symptoms. Chey: An FDA-approved product for #CSID is Sucraid (sacrosidase) Oral Solution enzyme from QOL Medical
  2. San Diego Convention Center Digestive Disease Week opening reception The social media meetup (Jeffrey Roberts is in the back row, 2nd from left with glasses) The awesome and talented Kate Scarlata, RD with Jeffrey Roberts MS, BSc Dr. Mark Pimentel and Jeffrey Roberts MS, BSc podcast recording Erica Dermer (@CeliacBeast) Gluten Free and Celiac Patient Influencer and Jeffrey Roberts MS, BSc DDW 50th Anniversary Sign The Rome Foundation Leadership Dr. Max Schmulson, Dr. Lin Chang, Dr. Jan Tack, Dr. Magnus Simrén,
  3. Getting ready for Digestive Disease Week #DDW19 in San Diego next week. I am honored to be selected as one of the Patient Influencer Travel Award recipients. I'll be reporting on the latest #IBS developments. Follow us on Twitter or Facebook @ibspatient or here our website.
  4. Chey: Small Intestinal Bacterial Overgrowth: Fact or Fiction? Chey: Small bowel Aspiration & Culture - an imperfect gold standard. Chey: Breath Testing has pros and cons based on the test used, ie: glucose or lactulose Chey: Which test is right? We don’t know. Exciting data coming from Mark Pimentel MD and Cedar-Sinai about this. Chey: Antibiotic regiment for SIBO with Rifaximin is recommended with a positive breath test Chey: Regardless of antibiotic employed for SIBO, a positive breath test seems to return Chey: Probiotics for SIBO - not statisti
  5. Olorinab for Abdominal Pain Associated with Crohn's Disease MD MagazinePreston Klassen, MD, head of research and development at Arena Pharmaceuticals, discusses olorinab's efficacy and safety for the treatment of abdominal pain ... View the full article
  6. FECAL MICROBIOTA TRANSPLANTATION (FMT) FOR IRRITABLE BOWEL SYNDROME (IBS): A SYSTEMATIC REVIEW AND META-ANALYSIS AuthorBlock: Dhruvan Patel1, Anisha Daxini2, Ramkaji Baniya3, Neilanjan Nandi1, Asyia S. Ahmad1 1Gastroenterology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States; 2Internal Medicine, Mercy Nazareth Hospital, Philadelphia, Pennsylvania, United States; 3Internal Medicine, Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States; Background: In recent years, the role of FMT in the treatment of IBS has been receivin
  7. Healio Gastroenterology In this video Dr. Chey, professor of medicine, and director of the GI Physiology Laboratory at University of Michigan Health System, discusses a state-of-the-art lecture he gave during the conference that highlighted how gastroenterologists, and even physicians, can keep to time and in turn, keep patients happy. https://www.healio.com/gastroenterology/practice-management/news/online/{c1e38310-a030-4a81-a36c-73dad8aa055a}/video-physicians-words-guide-patients-from-hopeless-to-hopeful
  8. Caterina Carco: The gut microbiome is thought to play a role in the mechanisms underlying gastrointestinal comfort and function.
  9. M. Pimentel: Second generation IBS blood test. Anti-CdtB and anti-vinculin using epitope optimization increases post-test probability of IBS to >98% (the basis for IBS-smart). M. Pimentel: Reduces unnecessary testing in IBS AND IBS is not in your head SECOND GENERATION ANTI-CDTB AND ANTI-VINCULIN TESTING PRODUCES GREATER DIAGNOSTIC ACCURACY FOR IBS-D COMPARED TO IBD Presentation Number: Sa1680 AuthorBlock: Walter Morales1, Ali Rezaie1,2, Stacy Weitsman1, Gillian Barlow1, Mark Pimentel1,2 1Medically Associated Science and Technology (MAST) Program, Cedars-Sinai Medical Cen
  10. Maya Pimentel (Cedar-Sinai): Elevated levels of Campylobacter jejuni in appendicitis (females n=50) seen in microbial DNA analysis. May support the use of antibiotics in a subgroup of patients with appendicitis.
  11. Lackner: Global IBS Symptom Improvement in Cognitive Bahvioral Therapy (CBT)
  12. Robyn Rexwinkel: Long-term follow-up of gut-directed hypnotherapy self-exercises at home using CD versus individual therapy by qualified therapists in children with #IBS or FGID pain (syndrome)
  13. Mayer & Lackner: Cognitive Behavioral Therapy (CBT) increased connectivity of brain networks in IBS Mayer & Lackner: Bacteriodes is also associated with symptom improvement after CBT which suggests changes in microbiota
  14. Camilleri: Tropifexor (LJN452), a non-bile acid FXR agonist, in patients with primary bile acid diarrhea and secondary its effect on transit time with small study (n=17) - safe, well tolerated,; however an increase in cholesterol was seen Camilleri: Summary of study: further exploration of Tropifexor may be worthwhile for this non-bile acid FXR agonist for functional diarrhea or IBS-D
  15. Wong: Ketotifen (inhibitor of allergic mediators) on GI visceral hypersensitivity and reduction of mast cells (MCs) in small study (n=48) of patients M/F with IBS-D had a positive outcome in GI symptoms and reduction of mast cells
  16. Caroline Tuck: Compliance with dietary interventions like low FODMAP diet is improved with Dietician support Caroline Tuck: Connecting patients with resources is important to ensure success Dr. Bellini: Reintroduction process helped patients identify fructose, polyls and GOS as food triggers they had not been aware of at baseline. Patients need a strategy for the FODMAP reintroduction process to optimize the learning process.
  17. Magnus Simren: A biomarker is a diagnostic tool for the identification of those patients with a disease or abnormal condition Magnus Simren: The Bristol Stool chart is used to determine stool type Magnus Simren: Visceral hypersensitivity and GI symptoms are strongly associated with FGiDs; however trials are limited for a biomarker which identifies positive outcomes for a specific treatment option Magnus Simren: SeHCAT testing might be helpful for determining who may respond to bile acid binding agents Magnus Simren: Potential biomarkers for IBS include anti-CdtB and an
  18. L Chang: Wide prevalence of comorbid conditions in IBS. Quality of Life (QOL) suffers with the greater number of conditions L Chang: FGiDs (Functional Gastrointestinal Disorders) and IBS comorbidities especially significant for women L Chang: Role for central neuromodulators (antidepressants) for managing FGiDs and IBS L Chang: Tricyclic antidepressants are considered first line for pain modulation. SSRI's antidepressants not as effective for GI pain. SNRI's antidepressants effective for pain. Tetracyclic antidepressants for early satiety, nausea/vomiting, weigh
  19. J Tack: GI Genius is a toolkit / algorithm from the Rome Foundation J Tack: Comorbidity with overlapping FGiD (Functional Gastrointestinal) conditions have more severe symptoms and seek more physician attention J Tack: FGiD (Functional Gastrointestinal) overlap is not uncommon. Sensorimotor disorders are often generalized and common mechanisms partially explain the overlap.
×
×
  • Create New...